Designed.
immunitoAI is a TechBio company developing AI-generated novel antibody therapeutics with pre-defined drug properties.
Our vision is to unleash the full potential of antibody-based biological drugs and make antibody therapy the norm.
Our AI platform generates novel antibody therapeutics with predefined drug characteristics for any protein target, validated through in-house biological methods.
immunitoAI's foundational pillars:
Design over Discovery, Drug-First Antibody, Structure-First AI Platform
Design over Discovery
in silico antibody design without biological sources
Intentional de novo antibody design
Increased efficiency and success rate
Expanding antibody space beyond nature’s repertoire
Drug-First Antibodies
We make drugs, not just biological molecules
Pre-defined drug properties embedded at inception
Computational screening of ideal characteristics
Minimised exploratory phase in drug developability
Structure-First AI Platform
Neural networks trained on shape complementarity
Precise target-specific design
Optimised affinity and specificity
Opens possibilities for undruggable targets
Join immunitoAI in our journey of "Making Antibody Therapy the Norm".